Skip to main content
Top
Published in: CEN Case Reports 1/2021

01-02-2021 | Tuberculosis | Case Report

Hypercalcemia caused by comorbid parathyroid adenoma and pulmonary tuberculosis

Authors: Sahoko Kamejima, Izumi Yamamoto, Arisa Kobayashi, Akio Nakashima, Taketo Uchiyama, Ichiro Ohkido, Takashi Yokoo

Published in: CEN Case Reports | Issue 1/2021

Login to get access

Abstract

Hypercalcemia is usually secondary to one etiology, although two coexisting etiologies can rarely cause hypercalcemia. Here, we report a 47-year-old woman with hypercalcemia caused by comorbid parathyroid adenoma and pulmonary tuberculosis. Primary hyperparathyroidism is the most common cause of hypercalcemia. Tuberculosis is a rare cause of hypercalcemia, but Japan continues to have an intermediate tuberculosis burden. Therefore, tuberculosis should be considered as a cause of hypercalcemia in Japan. Patients with tuberculosis are often asymptomatic, making the diagnosis difficult. In the previous cases in which these diseases coexisted, one disease was diagnosed after treatment of the other. In our case, the very high 1,25-dihydroxyvitamin D level (162 pg/mL) helped us to diagnose asymptomatic tuberculosis and both diseases were diagnosed promptly. It is necessary to consider comorbidities, including tuberculosis in a case with a very high 1,25-dihydroxyvitamin D level. We report a valuable case in which the early diagnosis and treatment of tuberculosis and primary hyperparathyroidism prevented the spread of tuberculosis.
Literature
1.
go back to reference Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991;6(Suppl 2):S51–9 (discussion S61).PubMed Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991;6(Suppl 2):S51–9 (discussion S61).PubMed
2.
go back to reference Hung KH, Chen FC, Hu YH, Chen JB, Hsu KT. Incidental primary hyperparathyroidism in a hypercalcaemic woman with tuberculous peritonitis. Int J Clin Pract. 2005;59(Suppl. 147):64–6.CrossRef Hung KH, Chen FC, Hu YH, Chen JB, Hsu KT. Incidental primary hyperparathyroidism in a hypercalcaemic woman with tuberculous peritonitis. Int J Clin Pract. 2005;59(Suppl. 147):64–6.CrossRef
3.
go back to reference Kar DK, Agarwal G, Mehta B, Agarwal J, Gupta RK, Dhole TN, et al. Tuberculous granulomatous inflammation associated with adenoma of parathyroid gland manifesting as primary hyperparathyroidism. Endocr Pathol. 2001;12:355–9.CrossRef Kar DK, Agarwal G, Mehta B, Agarwal J, Gupta RK, Dhole TN, et al. Tuberculous granulomatous inflammation associated with adenoma of parathyroid gland manifesting as primary hyperparathyroidism. Endocr Pathol. 2001;12:355–9.CrossRef
4.
go back to reference Jacob PM, Sukumar GC, Nair A, Thomas S. Parathyroid adenoma with necrotizing granulomatous inflammation presenting as primary hyperparathyroidism. Endocr Pathol. 2005;16:157–60.CrossRef Jacob PM, Sukumar GC, Nair A, Thomas S. Parathyroid adenoma with necrotizing granulomatous inflammation presenting as primary hyperparathyroidism. Endocr Pathol. 2005;16:157–60.CrossRef
5.
go back to reference Tuberculosis Surveillance Center. Tuberculosis in Japan—annual report 2018. Tokyo: Department of Epidemiology and Clinical Research, the Research Institute of Tuberculosis; 2018. Tuberculosis Surveillance Center. Tuberculosis in Japan—annual report 2018. Tokyo: Department of Epidemiology and Clinical Research, the Research Institute of Tuberculosis; 2018.
6.
go back to reference Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, et al. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol. 2008;159:719–27.CrossRef Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Rejnmark L, Brixen K, et al. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur J Endocrinol. 2008;159:719–27.CrossRef
7.
go back to reference Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr Rev. 2016;37:521–47.CrossRef Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: mechanisms, diagnosis, and treatment. Endocr Rev. 2016;37:521–47.CrossRef
8.
go back to reference Hanai S, Shinzato T, Inazu D, Tokuda Y. Hypercalcaemia caused by active pulmonary tuberculosis in an elderly person without fever or pulmonary symptoms. BMJ Case Rep. 2017;2017:bcr2016217797.CrossRef Hanai S, Shinzato T, Inazu D, Tokuda Y. Hypercalcaemia caused by active pulmonary tuberculosis in an elderly person without fever or pulmonary symptoms. BMJ Case Rep. 2017;2017:bcr2016217797.CrossRef
9.
go back to reference Ralph AP, Rashid Ali MRS, William T, Piera K, Parameswaran U, Bird E, et al. Vitamin D and activated vitamin D in tuberculosis in equatorial Malaysia: a prospective clinical study. BMC Infect Dis. 2017;17:312.CrossRef Ralph AP, Rashid Ali MRS, William T, Piera K, Parameswaran U, Bird E, et al. Vitamin D and activated vitamin D in tuberculosis in equatorial Malaysia: a prospective clinical study. BMC Infect Dis. 2017;17:312.CrossRef
10.
go back to reference Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab. 2018;103:3993–4004.CrossRef Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab. 2018;103:3993–4004.CrossRef
11.
go back to reference Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14:115–25.CrossRef Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14:115–25.CrossRef
12.
go back to reference Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence:CCBY-NC-SA3.0IGO. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Licence:CCBY-NC-SA3.0IGO.
13.
14.
go back to reference Komaba H, Ikeda K, Fukagawa M. Familial hypocalciuric hypercalcemia. Nihon Naika Gakkai Zasshi (J Jpn Soc Intern Med). 2007;96:681–7.CrossRef Komaba H, Ikeda K, Fukagawa M. Familial hypocalciuric hypercalcemia. Nihon Naika Gakkai Zasshi (J Jpn Soc Intern Med). 2007;96:681–7.CrossRef
15.
go back to reference Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes. 2011;18:359–70.CrossRef Christensen SE, Nissen PH, Vestergaard P, Mosekilde L. Familial hypocalciuric hypercalcaemia: a review. Curr Opin Endocrinol Diabetes Obes. 2011;18:359–70.CrossRef
16.
go back to reference Isaksen T, Nielsen CS, Christensen SE, Nissen PH, Heickendorff L, Mosekilde L. Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif Tissue Int. 2011;89:285–94.CrossRef Isaksen T, Nielsen CS, Christensen SE, Nissen PH, Heickendorff L, Mosekilde L. Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study. Calcif Tissue Int. 2011;89:285–94.CrossRef
17.
go back to reference Eller-Vainicher C, Falchetti A, Gennari L, Cairoli E, Bertoldo F, Vescini F, et al. Diagnosis of endocrine disease: evaluation of bone fragility in endocrine disorders. Eur J Endocrinol. 2019;180:R213–32.CrossRef Eller-Vainicher C, Falchetti A, Gennari L, Cairoli E, Bertoldo F, Vescini F, et al. Diagnosis of endocrine disease: evaluation of bone fragility in endocrine disorders. Eur J Endocrinol. 2019;180:R213–32.CrossRef
18.
go back to reference Schlatter E. Who wins the competition: TRPV5 or calbindin-D28K? J Am Soc Nephrol. 2006;17:2954–6.CrossRef Schlatter E. Who wins the competition: TRPV5 or calbindin-D28K? J Am Soc Nephrol. 2006;17:2954–6.CrossRef
Metadata
Title
Hypercalcemia caused by comorbid parathyroid adenoma and pulmonary tuberculosis
Authors
Sahoko Kamejima
Izumi Yamamoto
Arisa Kobayashi
Akio Nakashima
Taketo Uchiyama
Ichiro Ohkido
Takashi Yokoo
Publication date
01-02-2021
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 1/2021
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-020-00509-2

Other articles of this Issue 1/2021

CEN Case Reports 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.